

Databases and infrastructure for traceability

Data sharing

Lagos, Nigeria 18 September 2019

Speakers



- Gregory Goger, Supply Chain Track and Trace Project Manager, Abbvie, USA
- Dirk Van den Wouwer, Senior. Manager, EMEA
 Deployment Digital Identification and Traceability, Johnson
 Sohnson Supply Chain, Belgium





Gregory Goger

Global Market Manager Supply Chain Traceability Gregory has been a member of AbbVie's Supply Chain Traceability Operations group since 2011. In Gregory's role as a Global Market Manager, he works with local affiliates to ensure serialization and traceability regulations are understood and implemented correctly. Prior to joining AbbVie Gregory spent 17 years in software development and data management.

Gregory is currently a member of the GS1 Healthcare Leadership Team.



gregory.goger@abbvie.com





https://www.linkedin.com/in/gregory-goger-0765314/







We're a biopharmaceutical company.

We're guided by people, powered by passion and in awe of the possibilities ahead of us.

We're highly focused, research-oriented and patient-centric.


We are AbbVie.





Treating people

In 2018, AbbVie medicines helped





\$ A A A A &

Treating over

32+

conditions

abbvie

Agenda

Importance of Data

The Types of Data to Collect

How Much Data to Collect

Types of Reporting Models

Timeline and Development Considerations




Importance of Data to the Supply Chain

You receive a drug product with the barcode below

- It has a GTIN
- It has a serial number

Is it safe to use? How do you know?

The key lies in the data associated with that GTIN and serial number



Types of Data to Collect

What are some of the types of data to consider when building a traceability system?

- Master Data
- Commissioning Data
- Transaction Data
- Final Disposition

Master Data

What is master data?

- Gartner definition: Master data is the consistent and uniform set of identifiers and extended attributes that describes the core entities of the enterprise
- Good master data allows clear communication with a minimal amount of data being exchanged



Master Data - example

With the scan of a single GTIN, what master data could be retrieved for a given product?

- Product name (brand name and generic drug name)
- Dosage form (tablet, syringe...)
- Dosage strength
- Pack size
- Package type
- Who is the manufacturer
- Where is the product manufactured
- Registration date
- Storage conditions
- Picture of the product



Commissioning Data

How will members of the supply chain determine if a serial number is valid?

A data repository containing all of the valid, live serial numbers allows for verification to occur

As products are serialized within the country it should be the responsibility of the manufacturers to ensure the valid serial numbers are uploaded to the system

• In the case of imported product, it could be the manufacturer or the importer that uploads the data



Transaction Data

Transaction data is the history of an individual product's movement

Where has a serial number been?

Where is a serial number supposed to be? Is it there?





Final Disposition

Eventually an individual product will reach an end of life state

If the data repository clearly identifies that a serial number is no longer available for use, attempts to re-use serial numbers or product packaging can be detected

Common end of life states include:

- Sample
- Dispensed
- Destroyed



How Much Data to Collect

There are many opportunities for data collection, and many points of the supply chain at which that data could be collected

To determine how much data to collect, first you need to identify why you are collecting the data. What problems are you trying to solve?

Each scenario requires data from different components of the supply chain. Focus on the highest priorities first

Scenario	Supply Chain Components
Counterfeit detection	Manufacturers and dispensers
Diversion	Distribution Network
Reimbursement Management and Fraud	Dispensers and patients


abbvie

How Much Data to Collect

You must determine what you are willing to spend in terms of cost, resources and effort to collect the data

Each data element being collected adds to the complexity of the system

Additional transactions may increase the number of supply chain entities that are required to participate, or involve additional functions within those entities





What Type of System to Build?

There are 2 primary traceability models:


- Point of Dispense Verification
 - Currently implemented in the European Union
- Full Track and Trace
 - Currently implemented in Turkey and Argentina. Under development in the U.S.



Point of Dispense Verification Process




Point-of-Dispense Verification Process





Full Track and Trace Process





Comparison of Traceability Models

	Point of Dispense Verification	Full Track and Trace
Benefits	Provides ability to detect counterfeit product before dispense to patient	Full visibility to product movement throughout entire supply chain Identify potential issues earlier and trace anomalies back to a specific point in the supply chain
Ease of Implementation	Responsibility on manufacturers to post data, dispensers to verify data	All supply chain parties must scan product with every product movement. Aggregation becomes a necessity
System requirements	Minimum amount of data created. Fewest number of transactions	Volume of data, transaction count, number of parties connected to the system all significantly higher

Comparison of Traceability Models

Data is now a part of the supply chain. Here are some examples of data transmission requirements in both models:

- Point of Dispense Verification
 - If a dispenser scans a product and receives a "serial number does not exist" message. The product will not be immediately dispensed to the patient. Additional effort is now required to determine if the product is safe
 - Benefit: The system has protected the patient in the event that bad product has been introduced to the supply chain
 - False errors: A failure to upload the commissioning data will trigger a false error message. A patient is now being prevented from receiving good product. The dispenser is forced to spend extra time investigating the situation
 - Data requirements: A manufacturer must ensure commissioning data is uploaded prior to product reaching the point of dispense. This most commonly allows at least a period of days before false errors would occur
 - Challenge: In the event of a true counterfeit scenario, where was the counterfeit introduced into the supply chain?
 There is no data associated with this product



Comparison of Traceability Models

Data is now a part of the supply chain. Here are some examples of data transmission requirements in both models:

- Full Track and Trace
 - A hospital receives a shipment of product, scans it, and attempts to upload a "receive" event. The system returns an error message stating there is no "ship" event. The hospital moves the product to quarantine while the situation is investigated
 - Benefit: The hospital has kept illegitimate product out of inventory and safely away from patients. A potential issue with a supplier has been revealed
 - False Errors: The distributor may have simply failed to upload the "ship" event. This is good product now sitting in quarantine due to a data issue
 - Data Requirements: The distributor must have data uploaded within hours of shipping product. An outage with the data repository may even cause distributors to delay shipments for fear of triggering false error messages
 - Challenge: Physical product and the data must move together. Data issues can stop the physical product, and the entire supply chain must stay connected to the data repository



Reporting System Timeline

Once a reporting model has been decided on when do you start building the reporting system and data repository? **VERY EARLY IN THE PROCESS**

GS1 Healthcare's Traceability Roadmap shows an example timeline for implementing traceability




https://www.gs1.org/industries/healthcare (Regulatory Roadmap link)



Repository Development Considerations


There is a natural dependency between data repository development and industry solution development





Repository Development Considerations

Once a data repository goes live, how will you get everyone connected?





Repository Development Considerations

Development of the data repository is critical for the entire supply chain

Solutions and standards exist. Take advantage of those standards. Implementation will be faster, cheaper and easier to maintain if the system is built using existing technology



People. Passion. Possibilities.®

AbbVie.com

AbbVie.com/Responsibility



Dirk Van den Wouwer

Sr. Mgr. EMEA Deployment Digital Identification and Traceability, Johnson & Johnson Supply Chain

Mr. Van den Wouwer has a Master in Bio Engineering and Master in Industrial Management Sciences. He worked for 15 years at Mars Inc. In various Supply Chain Management functions. In 2007 he joined Johnson & Johnson in the planning department, leading the chemical platform planning department. Since 5 years he is responsible for Serialization and Traceability deployment in EMEA region where he has successfully implemented the European regulation for Medicines Verification. Since 6 months he is also in charge of Unique Device Identification and Global Data Synchronization across EMEA.



dvdwouwe@its.jnj.com





LinkedIn




Product Data, Databases & Infrastructure Supporting Traceability

Deployment in a global company

Dirk Van den Wouwer EMEA Deployment, Digital Identification &Traceability GS1 Healthcare Conference, Lagos, Nigeria September 2019

Johnson Johnson



Johnson & Johnson

World's largest and most broadly based healthcare company

- Over 130 years of caring
- Selling products in more than 175 Countries
- Approximately 130,000 employees worldwide





Our Credo

Johnson Johnson

We believe our first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs, everything we do must be of high quality. We must constantly strive to provide value, reduce our costs and maintain reasonable prices. Customers' orders must be serviced promptly and accurately. Our business partners must have an opportunity to make a fair profit.

We are responsible to our employees who work with us throughout the world. We must provide an inclusive working environment where each person must be considered as an individual. We must respect their diversity and dignity, and recognise their merit. They must have a sense of security, fulfilment and purpose in their jobs. Compensation must be fair and adequate, and working conditions clean, orderly and safe. We must support the health and well-being of our employees, and help them fulfil both their family and other personal responsibilities. Employees must feel free to make suggestions and complaints. There must be equal opportunity for employment, development and advancement for those qualified. We must provide highly capable leaders, and their actions must be just and ethical.

We are responsible to the communities in which we live and work, and to the world community as well. We must help people to be healthier by supporting better access and care in more places around the world. We must be good citizens – by supporting good works and charities, improving health and education, and bearing our fair share of taxes. We must maintain in good order the property we are privileged to use, protecting the environment and natural resources.

Our final responsibility is to our stockholders. Business must make a sound profit. We must experiment with new ideas. Research must be carried on, innovative programmes developed, investments made for the future and mistakes paid for. New equipment must be purchased, new facilities provided and new products launched. Reserves must be created to provide for adverse times. When we operate according to these principles, the stockholders should realise a fair return.

Johnson & Johnson Portfolio

Consumer

Self Care • Skin Care • Essentials



Medical Devices


Wound Closure & Surgical Devices • Minimally Invasive Surgery • Joint Replacement Sterilization • Eye Health • CSS



Pharmaceuticals


Oncology • Infectious Diseases & Vaccines • Immunology • Cardiovascular & Metabolism • Neuroscience & Pain • Pulmonary Hypertension • PAH





Deploying for Regulations Requires Managing **Through Complex Organizational Structures**

Organizing in a global, end-to-end, cross-functional context



Traceability Touches Multiple Domains


Assessment required over different parts of the business





Traceability Entails an Integrated Systems & Processes Approach

Enabled by GS1 Global Standards (GTIN, GLN, SSCC, EPCIS,...)





EU Falsified Medicines Directive Published in July 2011

Serialization only part of the directive

Product Safety Features

Authenticity

Pack Identity

Tamper Evidence

Feb 9, 2019

Good Distribution

Wholesalers & Brokers

GDP

2014-Q1

Active Substances

GMP for Excipients

Jan 2, 2013

Registration API
Activities

July 2, 2013





Delegated Act Mandates Rules for End-to-End Verification

Key pillars of serialization and verification published Feb 2019

Serialization by manufacturer

+

Verification at point of dispense


Unique identifier +

Tamper evidence

System set up and governed by stakeholders under supervision of local authorities

Manufacturers pay for the system








Point of Dispense Verification

All parties verify against one central system






European Repositories Systems



Enable systematical point of dispense verification








Piloting the German National System


Proven technology ... knowledge gained by executing





Phased Roll Out Across 30 Countries

Supported by realistic time plans, monitored centrally





2019





Key Attention Points

Build on experience gained in other countries



Game Changer



Multi-Country Packs



Special Flows



Regulatory Reporting




Know How

- Full end-to-end process
- Impacting all business units, partners, systems & platforms
- Refrain from using NTIN
- Alignment on National Reimbursement number
- Marketing Authorization Holder
- Producer
- Distributor
- Clear specifications needed upfront
- Alignment to industry standards
- · Reuse experience build by stakeholders
- Cost & timings of implementation decreases as capabilities are being deployed



End-to-End Verification Process Requiring System Integration



Phased Approach Realistic Timings Recommended



GTIN 01234567890128

EXP 12-2018 LOT 123456



Phase 1: Product Identification

- DataMatrix including GTIN, Batch #, Expiry date
- Suggested Timing: ~6 to 12 months as of publication


01234567890128 123456789012

12-2018 123456



Phase 2: Unique Identification of Secondary Pack

- Include serial number in DataMatrix
- Suggested Timing: ~6 to 18 months as of publication



Phase 3: End-to-End Traceability / Verification

- Including reporting to Health Authorities
- Suggested Timing: ~24 to 36 months as of publication

Thank you.





Questions





Gregory Goger, Abbvie

Dirk Van den Wouwer, Johnson & Johnson



Thanks to our co-host & conference partners













Thanks to our sponsor






Follow us on Twitter and tweet about the conference!



@GS1Healthcare #GS1HCLagos





Be sure to complete each feedback form!





For every feedback form completed, we will donate 5USD to the chosen conference charity "The North East Children Trust"

https://healthcarenigeria.gs1.org/



Need any help? Contact us!



Look for the turquoise scarves and ties - we are happy to help you!









COFFEE BREAK



Afternoon at a glance



Tuesday 17 September 2019			
13:00-14:30	General Networking lunch & visit of marketplace		
14:30-15:45	Two parallel streams		
	Stream I - Government and regulatory body Think Tank- Learning from other countries and regions	Stream II - Establishing Traceability: the building blocks	
15:45-16:15	Coffee break		
16:15-17:30	Two parallel streams		
	Stream I - Government and regulatory body Think Tank- Learning from other countries and regions	Stream II - Databases and infrastructure for traceability	



Afternoon at a glance



Wednesday 18 September 2019			
13:10-14:15	General Networking lunch & visit of marketplace		
	Two parallel streams		
14:15-15:45	Stream I – Government and regulatory body Think Tank – Discussing the possibility of regulatory alignment across Africa	Stream II – Traceability – global status – developments worldwide	
15:45-16:15	Coffee break		
16:15-17:45	Two parallel streams		
	Stream I – Government and regulatory body Think Tank – Discussing the possibility of regulatory alignment across Africa	Stream II – Data as the base for supply chain	




GS1 Healthcare Digital Thread



An interactive representation of the application of GS1 standards in healthcare in a simple and powerful way.

Test it at the Marketplace!





Visit the Marketplace during lunch time



Meet the exhibitors in the Mezzanine level of Orchid Hall **Every day during breaks and lunch**













Networking event at The Civic Centre tonight at 19:00



The Civic Centre

Ozumba Mbadiwe Avenue Opposite 1004, Victoria Island Lagos, Nigeria

PLEASE WEAR YOUR EVENT BADGE ©

Bus departure: meet in the main hotel lobby at 19:00 sharp!

Bus return: beginning at 21:30 shuttle buses will take you back to the EKO Hotel

Dress code: Business casual





Join us at the to ask experts your questions





The answer to all your questions!

- After lunch today, during a 2 hours session
- meet the experts in Lantana Hall



Thank you



